Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone + TKI in CML Patients After Failed TKI Discontinuation
NCT02889003Phase 2Recruiting
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Dec 2016
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pioglitazone in chronic myeloid leukemia (CML), sponsored by Centre Hospitalier de Versailles. Started Dec 2016; status: recruiting.
02
Drugs
pioglitazone
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02889003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889003.